文献速递造血干细胞移植与细胞治疗

慢性移植物抗宿主病:未解决的并发症还是历史?

Chronic graft-versus-host disease: unresolved complication or ancient history?
PubMed 文献 · Blood · 2024-01-01

本文综述慢性移植物抗宿主病(cGVHD)的疾病负担、生物学进展、美国国立卫生研究院(NIH)共识会议对诊断、分期和反应标准的完善、介入试验确立的治疗结局基准,以及美国食品药品监督管理局(FDA)已批准3种药物治疗激素难治性cGVHD;作者提出应批判性审视当代GVHD预防方案的结果,讨论cGVHD风险相关争议,并强调基础与临床研究支持对改善患者结局至关重要。

要点

  • cGVHD与异基因造血细胞移植(HCT)后发病率、死亡率、生活质量受损、免疫抑制治疗延长和感染风险相关。
  • 美国国立卫生研究院(NIH)共识会议完善了cGVHD诊断、分期和反应标准的严格方法。
  • 美国食品药品监督管理局(FDA)迄今已批准3种药物治疗激素难治性cGVHD。

核心结论

  • 作者提出应批判性审视当代GVHD预防方案的结果,讨论cGVHD风险相关争议,并认为支持基础与临床研究对改善患者结局至关重要。

研究设计与样本

  • 综述:回顾现有证据,讨论cGVHD的疾病负担、生物学进展、诊断分期标准、治疗试验基准及预防策略争议。

主要发现

  • cGVHD与异基因造血细胞移植(HCT)后发病率、死亡率、生活质量受损、免疫抑制治疗延长和感染风险相关。
  • 美国国立卫生研究院(NIH)共识会议完善了cGVHD诊断、分期和反应标准的严格方法。
  • 大型介入试验已确立治疗结局的标准基准。
  • 美国食品药品监督管理局(FDA)迄今已批准3种药物治疗激素难治性cGVHD。
  • 近期多项试验的有希望结果使部分人认为cGVHD风险已足够低,可视为过去的主要移植后并发症,但另一些人未得出此结论。

关键数值与推荐

  • 美国食品药品监督管理局(FDA)迄今已批准3种药物治疗激素难治性cGVHD。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic graft-versus-host disease (cGVHD) is associated with morbidity, mortality, impaired quality of life, prolonged immunosuppressive therapy, and infection risk after allogeneic hematopoietic cell transplantation (HCT). Major strides have occurred in the understanding of cGVHD biology; National Institutes of Health Consensus meetings have refined rigorous approaches to diagnosis, staging, and response criteria; major interventional trials have established standard benchmarks for treatment outcome; and 3 agents to date have been US Food and Drug Administration approved for treating corticosteroid-refractory cGVHD. Promising results from several recent trials have led some, but not others, to conclude that the risk of developing cGVHD is sufficiently low to be considered a major post-HCT complication of the past. We propose that it is time to critically examine the results of contemporary graft-versus-host disease (GVHD) prophylaxis regimens and discuss the state of the science and associated controversies in the spectrum of conclusions reached as to the risk of cGVHD. With these data, the current cGVHD incidence can be most precisely determined, and the present and future burden of cGVHD-affected patients can be accurately modeled. Through review of existing evidence, we highlight unresolved needs and opportunities to refine best GVHD prophylaxis or preemptive therapy approaches and optimize established cGVHD therapy, and make the argument that support of preclinical and clinical research is critical in improving patient outcomes.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pidala JA, Gooley TA, Luznik L, et al. Chronic graft-versus-host disease: unresolved complication or ancient history? Blood. 2024. PMID: 39008818. doi:10.1182/blood.2023022735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。